About this Research Topic
Urothelial cancer (UC) is classified as the most common type of bladder cancer. Studies have demonstrated the first-line treatment for metastatic UC patients is platinum-based chemotherapy which utilizes gemcitabine with cisplatin or gemcitabine followed by carboplatin dependent on whether the patient is unable to proceed with cisplatin. However, further research is required to develop treatment options for patients to reduce the high recurrence rate and the poor prognosis and survival rate for patients. There has been development in the therapeutic and treatment approaches for UC patients revolving around the growing field of immunotherapy, particularly the use of immunotherapy with checkpoint inhibitors.
Studies have demonstrated the advantages of immune checkpoint inhibitors to be utilized as a potential therapeutic option in many cancers. Particularly in bladder cancer, high expression levels of programmed death-ligand 1 (PD-L1) demonstrates advanced and aggressive tumors with poor prognosis and survival rates. Atezolizumab has been found to be the first PD-L1 inhibitor approved in 2016 and with further research and studies, more immune checkpoint inhibitors including Nivolumab, Pembrolizumab, Avelumab, and Durvalumab have been identified to have a positive impact in UC patients. However, further research is required to understand how the immune checkpoint inhibitors impact patients and the molecular mechanisms influencing the cancer.
The goal of this Research Topic is to explore how immunotherapy impacts and influences urothelial cancer, particularly focusing of immune checkpoint inhibitors and tumor microenvironment. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Studies have demonstrated the advantages of immune checkpoint inhibitors to be utilized as a potential therapeutic option in many cancers. Particularly in bladder cancer, high expression levels of programmed death-ligand 1 (PD-L1) demonstrates advanced and aggressive tumors with poor prognosis and survival rates. Atezolizumab has been found to be the first PD-L1 inhibitor approved in 2016 and with further research and studies, more immune checkpoint inhibitors including Nivolumab, Pembrolizumab, Avelumab, and Durvalumab have been identified to have a positive impact in UC patients. However, further research is required to understand how the immune checkpoint inhibitors impact patients and the molecular mechanisms influencing the cancer.
The goal of this Research Topic is to explore how immunotherapy impacts and influences urothelial cancer, particularly focusing of immune checkpoint inhibitors and tumor microenvironment. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: urothelial cancer, genitourinary oncology, cancer, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
